CYP19A1 rs6493497: Understanding Aromatase Inhibitor Response
The rs6493497 variant is a genetic change located within the CYP19A1 gene, which provides instructions for the aromatase enzyme. Research suggests this variant may influence how an individual's body processes and responds to aromatase inhibitor medications used in breast cancer therapy.
What each genotype means
Baseline aromatase activity
This genotype is considered the common or wild-type form in many populations. Research suggests that individuals with this genotype may experience different changes in aromatase activity during treatment with aromatase inhibitors compared to those carrying the A allele. Please discuss your treatment plan and any concerns regarding medication efficacy with your clinician or pharmacist.
This is the most common genotype in many global populations, though frequencies vary significantly by ancestry.
Altered aromatase response
Carriers of this genotype have been observed to show a greater change in aromatase activity when treated with aromatase inhibitors like anastrozole or letrozole. While this may suggest increased drug target engagement, some studies indicate it does not necessarily lead to a greater reduction in circulating estradiol levels. Please consult your healthcare provider to discuss how this may relate to your specific clinical management.
This genotype is found in a subset of the population, with frequencies varying by ethnic background.
Increased aromatase expression potential
This genotype is associated with the variant allele, which has been linked in some studies to higher baseline aromatase expression and increased estradiol levels following treatment with certain aromatase inhibitors. Because this variant is in tight linkage with other genetic markers, its effects are complex and may influence how your body responds to hormone-blocking therapies. Always discuss your medication dosing and therapeutic response with your oncology team.
This is the less common genotype, with its prevalence varying significantly across different ancestral groups.
What is rs6493497 and Where is it Located?
The rs6493497 variant is a single nucleotide polymorphism (SNP) found within the CYP19A1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in an intronic region of the gene, meaning it sits within a non-coding sequence that does not directly provide the blueprint for the protein structure itself. However, intronic variants can still play critical roles in regulating how much of a protein is produced or how the gene is expressed in different tissues. Scientists often study these markers to understand why individuals may have different baseline levels of enzyme activity or varying responses to medical treatments that target specific biological pathways.
The Role of the CYP19A1 Gene
The CYP19A1 gene is responsible for encoding the aromatase enzyme. Aromatase is a crucial component of the endocrine system, functioning as a catalyst in the biosynthesis of estrogens from androgens. By converting these hormones, aromatase helps maintain the balance of sex steroids in the body. Because estrogen can promote the growth of certain types of breast cancer cells, aromatase inhibitors are frequently used as a therapeutic strategy to block this enzyme's activity, thereby lowering estrogen levels. Understanding the genetic variations within CYP19A1 is important because differences in the gene's expression or the enzyme's efficiency can theoretically impact how effectively these medications work in a clinical setting.
Research Associations and Evidence Strength
Current research into rs6493497 has identified associations between this variant and changes in aromatase activity among patients undergoing treatment with aromatase inhibitors like anastrozole, exemestane, and letrozole. Studies have observed that carriers of the variant allele may show a greater decrease in aromatase activity during treatment, suggesting a potential link to drug efficacy. However, some findings are complex; for instance, while some data suggest higher drug efficacy, other studies have noted that variant carriers might exhibit higher plasma estradiol levels post-treatment. Because these results can vary between studies and are often based on specific patient cohorts, the evidence strength is considered moderate. It is essential to recognize that these findings are statistical associations observed in research populations and do not necessarily predict an individual's specific clinical outcome.
Population Frequency
The frequency of the rs6493497 variant is known to vary significantly across different ancestral populations. Genetic databases indicate that the distribution of the A and G alleles is not uniform globally, which is a common characteristic of many human genetic variants. Because frequency data can be highly specific to the ethnic background of the study participants, researchers emphasize that findings from one population may not be directly applicable to another. Understanding these frequency differences is a key part of pharmacogenomic research, as it helps scientists account for genetic diversity when evaluating how different groups might respond to the same medical interventions.
What You Can and Cannot Do With This Information
Genetic information regarding rs6493497 is intended for educational purposes and to provide insight into the complex relationship between genetics and drug response. It is important to understand that this information is not a diagnostic tool and cannot be used to predict how a specific person will respond to a medication. Clinical decisions regarding breast cancer treatment are highly individualized and based on a wide range of factors, including tumor characteristics, overall health, and established clinical guidelines. If you are interested in how your genetic profile might relate to your treatment plan, you should discuss this with your oncologist or a clinical pharmacist. They are the only professionals qualified to interpret genetic data in the context of your specific medical history and to make decisions regarding your care.
How common is this variant?
The frequency of the rs6493497 variant varies by ethnicity, with different populations showing distinct distributions of the A and G alleles.
Frequently asked questions
Does rs6493497 mean I will have a bad reaction to breast cancer medication?
No, this variant is not a predictor of adverse reactions. It is a subject of research regarding how the body processes medication, and any concerns about side effects or treatment efficacy should be discussed directly with your healthcare provider.
Should I get a genetic test for CYP19A1?
Genetic testing for this variant is not currently a standard part of clinical care for breast cancer. You should consult with your doctor to determine if any genetic testing is relevant or necessary for your specific treatment plan.
Can I change my genotype for rs6493497?
No, your genotype is determined at conception and cannot be changed. Genetic variants are inherited from your parents and remain constant throughout your life.
Where can I find more information on pharmacogenomics?
You can find reliable information on pharmacogenomics through resources like the NIH's MedlinePlus Genetics or the Pharmacogenomics Knowledge Base (PharmGKB). These sites provide educational materials on how genes influence drug response.
Sources & further reading
Educational information only, last refreshed 10/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6493497?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP19A1
This SNP is in tight linkage with rs6493497 and contributes to the genetic modulation of aromatase activity and clinical response to endocrine therapy.
Affects aromatase activity, influencing efficacy and toxicity in hormone-sensitive cancer treatments.
This variant in the aromatase gene is associated with variations in sex hormone levels and potential risk modulation for hormone-dependent reproductive cancers.
Aromatase gene polymorphism associated with circulating estradiol levels and altered susceptibility to postmenopausal osteoporosis and breast cancer.
Aromatase single-nucleotide variant modulating estrogen biosynthesis efficiency and postmenopausal hormone levels.
Intronic aromatase variant linked to variation in circulating estradiol levels and timing of natural menopause.